JPRN-UMIN000043994已完成未知
Comparative efficacy and safety of lorlatinib and alectinib for ALK rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: systematic review and network meta-analysis. - lorlatinib versus alectinib
Showa University school of medicine0 个研究点目标入组 2,194 人开始时间: 2021年4月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2,194
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 18years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Studies for children Observational studies
研究者
相似试验
招募中
不适用
Evaluation of lorlatinib efficacy of patients with EML4-ALKALK positive lung cancerJPRN-UMIN000042617Japanese Society of Lung Cancer150
已完成
不适用
Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patientsconstipation-predominant irritable bowel syndromeJPRN-UMIN000028709Kawasaki Medical School50
已完成
不适用
Comparison of efficacy of two ophthalmic drops on decreasing intraocular pressureGlaucoma.Glaucoma, Glaucoma suspectH40, H40.0IRCT2015042021875N1Vice chancellor for research and technology of Islamic Azad University of Shahrood40
已完成
3 期
A clinical trial to study and compare the effects of two once a daily eye drops in patients with open angle Glaucoma and ocular hypertension.CTRI/2011/12/002313Sun Pharma Advanced Research Company Ltd100
尚未招募
Unknown
Real world study of lorlatinib in previously untreated ALK positive lung cancerCTRI/2024/03/063721Pfizer Products India Private Limited